169 related articles for article (PubMed ID: 19374023)
1. The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate.
Maayan L; Paykina N; Fried J; Strauss T; Gugga SS; Greenhill L
J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):147-53. PubMed ID: 19374023
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
[No Abstract] [Full Text] [Related]
3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
4. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
[TBL] [Abstract][Full Text] [Related]
5. Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):342-349. PubMed ID: 34081560
[No Abstract] [Full Text] [Related]
6. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
[TBL] [Abstract][Full Text] [Related]
9. Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.
Wigal SB; Childress A; Berry SA; Belden HW; Chappell P; Wajsbrot DB; Nagraj P; Abbas R; Palumbo D
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):314-321. PubMed ID: 29641237
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
Vitiello B; Abikoff HB; Chuang SZ; Kollins SH; McCracken JT; Riddle MA; Swanson JM; Wigal T; McGough JJ; Ghuman JK; Wigal SB; Skrobala AM; Davies M; Posner K; Cunningham C; Greenhill LL
J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):593-604. PubMed ID: 17979580
[TBL] [Abstract][Full Text] [Related]
11. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
[TBL] [Abstract][Full Text] [Related]
12. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
[TBL] [Abstract][Full Text] [Related]
15. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
Buitelaar JK; Casas M; Philipsen A; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; van Oene JC; Schäuble B
Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214
[TBL] [Abstract][Full Text] [Related]
16. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
[TBL] [Abstract][Full Text] [Related]
17. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
18. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
19. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.
Rösler M; Fischer R; Ammer R; Ose C; Retz W
Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):120-9. PubMed ID: 19165529
[TBL] [Abstract][Full Text] [Related]
20. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
Yılmaz S; Bilgiç A; Hergüner S
J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
